Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
-Triggers $5 Million Payment from Roche-
MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it has achieved the enrollment goal for its Phase 2 trial of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cogni...
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today-
MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ --
Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today
announced that Roche has ex...
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
- Establishes Plan for Biomarker Study -
MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory
Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it plans to
conduct a clinical study of MEM
3454, the Company's lead nicotinic alpha-7
partial agonist, on two biomarker...
Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
-Company to Host Conference Call at 9:00 a.m. EDT-
MONTVALE, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Memory
Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced top-line data from the
multi-center, randomized, double-blind, placebo-controlled Phase 2a study
1003, a neuronal...
Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
...munity. The Company
reported new clinical data for mem
1414, its lead PDE4 inhibitor,
demonstrating the c... in humans. In addition, the
Company has nominated mem
68626 as the lead development candidate from its
5...r, we are pleased to report that we have
68626 as the lead compound in our 5-HT6 antagonist...
Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
...ths, highlighted by our positive Phase 2a
data for mem
3454 in Alzheimer's disease, the expansion of our
schizophrenia development program for mem
3454 with our partner Roche, and
the completion of...4996/MEM 63908, and initiate a biomarker study for mem
Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory
Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced dosing of the first
subject in a randomized, double-blind, placebo-controlled Phase 2a clinical
trial of MEM
3454, the Company's lead nicotinic alpha-7 receptor partial
agonist, in c...
Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
... previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an mem
from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania.
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
...E10 inhibitor program and from SMRI related to the mem
program which were recognized in 2007 but not...administrative costs and costs associated with the mem
General and administrative expense...ory
Pharmaceuticals presented preclinical data for mem
68626, its lead 5-HT6
antagonist, in a poster pres...
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
...nd our Phase 1
program for R4996/MEM 63908, initiating a Phase 2a trial for mem
advancing our 5-HT6 antagonist program into the clinic."
Financ... $3.4 million decrease in costs
associated with the clinical development of mem
General and administrative expenses for the quarter ended March 31,...
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
...lpha-7 Receptor Agonist Collaboration with Roche. mem
3454, the lead compound in the Company's ni...y expects to initiate a biomarker study for mem
3454 in schizophrenia this summer, with res...expects to complete its Phase 1 program for mem
63908 and report top-line results in the fourth qu...
Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
...will receive approximately $55 million of net offering
proceeds, after underwriting discounts and estimated costs. Merriman Curhan Ford & Co. (Amex: mem
) acted as the sole book-running
manager in this offering, and Dawson James Securities, Inc. acted as
co-manager. Copies of the final prospectus may ...
Agendia BV Appoints Clinical and Scientific Advisory Board
...esearch programs and provide critical
evaluations from academic and clinical perspectives. Agendia welcomes: Piet Borst (chair), M.D., PhD, CBE, For mem
RS, Staff Member and
Emeritus Director of the Netherlands Cancer Institute and Professor of
Clinical Biochemistry, Amsterdam, The Netherlands Jose Ba...
Bionovo Announces Proposed Public Offering of Common Stock
...al Markets Corp. and Canaccord Adams Inc. are acting as joint
book-running managers for the proposed offering, with Merriman Curhan Ford
& Co. (Amex: mem
) acting as a co-manager. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sal...
Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
mem (Sigma) containing 10% (v/v) FBS, 200 µ g/ml G418, L-glutamine, non-essential amino acids
Assay medium: mem (Sigma)
Agonist: Isoproterenol (Sigma)
The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies
...EK293 cell line expressing EGF receptor
HEK Culture medium: mem
(Sigma M2279) containing:
10% (v/v) FBS
4. Replace the culture medium with 100 µl/well of fresh mem (phenol red free) containing 2.5–5 µg/ml CypHer5E anti-VSV-G an...